People: AEterna Zentaris Inc (AEZS.O)

AEZS.O on Consolidated Issue listed on NASDAQ Capital Market

1.15USD
17 Apr 2014
Price Change (% chg)

$0.03 (+2.68%)
Prev Close
$1.12
Open
$1.13
Day's High
$1.16
Day's Low
$1.12
Volume
302,936
Avg. Vol
1,137,506
52-wk High
$2.18
52-wk Low
$0.99

Search Stocks

Lapalme, Pierre 

Brief Biography

Mr. Pierre Lapalme is Independent Director of AEterna Zentaris Inc. Mr. Lapalme has, over the course of his career, held numerous senior management positions in various global life sciences companies. He is former Senior Vice President, Sales and Marketing for Ciba-Geigy (which subsequently became Novartis) and former Chief Executive Officer and Chairman of the Board of Rhone-Poulenc Pharmaceuticals Inc. in Canada and in North America, as well as Executive Vice President and Chief Executive Officer of Rhone-Poulenc-Rorer Inc. North America (now sanofi-aventis), where he supervised the development, manufacturing and sales of prescription products in North and Central America. Mr. Lapalme served on the Board of Directors of the National Pharmaceutical Council USA and was a member of the Board of Directors of the Pharmaceutical Manufacturers Association of Canada, where he played a leading role in reinstituting patent protection for pharmaceuticals. Until recently, he was a member of the Board and Chairman of the Board of Sciele Pharma Inc., which was acquired by Shionogi and Co. Ltd. Mr. Lapalme is currently Chairman of the Board of Biomarin Inc., Chairman of the Board of Pediapharm Inc., Chairman of the Board of GlyPharma Therapeutics and a member of the Board of Directors of Algorithme Pharma Inc. and of Insy's Therapeutics Inc., a Phoenix-Arizona based specialty pharma company. He studied at the University of Western Ontario and at INSEAD, France.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Juergen Ernst

120,250

David Dodd

1,279,000

Dennis Turpin

403,092

Richard Sachse

--

Jude Dinges

259,884

Elliot Shapiro

--
As Of 30 Dec 2013
Search Stocks